Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
21°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gh Research Plc
(NQ:
GHRS
)
6.240
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gh Research Plc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
November 23, 2023
Via
Benzinga
GH Research Drags Down Psychedelic Drug Stocks Index By 7%
November 23, 2023
The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week.
Via
Talk Markets
Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 22, 2023
Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results.
Via
Benzinga
HP, Iridium Communications And Other Big Stocks Moving Higher On Wednesday
November 22, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Wednesday. Shares of HP Inc. (NYSE: HPQ) gained during Wednesday’s session following quarterly results.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
GH Research: Steady Expenses And $229M Cash Position For 2026 Runway
November 14, 2023
The clinical-stage psychedelics biotech GH Research PLC (NASDAQ: GHRS) reported its financial results for Q3 2023 ended September 30, showing:
Via
Benzinga
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart
November 11, 2023
Our Psychedelic Drug Stocks Index continues to exhibit extreme volatility, declining 8% this week, jumping 22% the previous week and falling 6.5% the week before that. This week's decline is based on...
Via
Talk Markets
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
November 06, 2023
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22%
November 05, 2023
The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances.
Via
Talk Markets
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
October 29, 2023
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
General Dynamics, Microsoft, Waste Management And Other Big Stocks Moving Higher On Wednesday
October 25, 2023
U.S. stocks traded lower, with the Nasdaq Composite falling more than 1% on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
October 22, 2023
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts
Via
Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution
Via
Benzinga
Exposures
Product Safety
Psychedelic-Compound-Based Drug Stocks Continue To Fall
October 15, 2023
The 5 constituents in our Psychedelic Drug Stocks Index were down 10.1% this week (-6.3% last week) and are now down 39.2% since the end of July.
Via
Talk Markets
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
October 06, 2023
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
Via
Benzinga
Major Psychedelic Drug Stocks Continued To Decline This Week
October 06, 2023
A review of the performances of the 5 stocks in the Psychedelic Drug Stocks Index this week and since the end of August along with links to their latest news.
Via
Talk Markets
GH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold
October 02, 2023
After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s (NASDAQ: GHRS) Investigational New Drug (IND) application for a Phase 1 clinical trial of proprietary...
Via
Benzinga
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
October 02, 2023
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...
Via
Benzinga
September Summary: Largest Psychedelic Drug Stocks Dropped 14%
October 01, 2023
Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining...
Via
Talk Markets
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
September 26, 2023
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price
September 24, 2023
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and...
Via
Talk Markets
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
September 18, 2023
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Via
Benzinga
Exposures
Product Safety
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week
September 17, 2023
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week...
Via
Talk Markets
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
6 Largest Psychedelic Compound-Based R & D Stocks In Decline
September 10, 2023
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD.
Via
Talk Markets
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
September 05, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD.
Via
Talk Markets
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via
Benzinga
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
September 02, 2023
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD.
Via
Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
August 28, 2023
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.